Ori Biotech

Ori Biotech is a private, platform technology company addressing the critical bottleneck in cell and gene therapy: scalable, cost-effective, and high-quality manufacturing. Its core product, the IRO® platform, combines a novel bioreactor with automated sterile connection technology (Ori Connect™) and digital tools to automate manual processes from R&D through GMP production. By eliminating the traditional trade-off between automation and biological performance, Ori aims to derisk and accelerate the path to commercial viability for CGT developers, ultimately seeking to improve patient access. The company is in a pre-revenue/early revenue stage, building its commercial footprint through strategic partnerships with leading research institutes and therapy developers.

The IRO® platform is an automated, flexible, and scalable cell and gene therapy manufacturing system. It combines a novel bioreactor with automated sterile connection technology (Ori Connect™) and a cloud-native digital suite. It is designed to eliminate the trade-off between automation and biological performance, aiming to improve cell quality, yield, and potency while increasing throughput, reducing costs, and minimizing batch failures from R&D through GMP production.

The competitive landscape includes established life science tool companies (e.g., Thermo Fisher, Sartorius, Miltenyi) offering bioreactors and processing systems, as well as specialized CGT manufacturing technology firms (e.g., Lonza, Cryoport, Berkeley Lights). Competition is focused on delivering closed, automated, and scalable solutions. Ori differentiates by emphasizing a 'biology-first' approach that claims no trade-off between automation and cell quality.